Healthcare / BiotechnologyTaipei Exchange
$51.20
+0.10 (+0.20%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-486.7M · quality 66.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$24.5B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-10.1%
↓Gross Margin
30.9%
↓Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-50.5%
FCF CAGR
—
FCF margin
-377.0%
FCF / Net income
0.47x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $129.1M · net income $-1.04B · FCF $-486.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $129.1M | $129.1M | $117.9M | $86.8M | $1.07B |
| Net Income | $-1.04B | $-1.04B | $-1.17B | $-1.31B | $360.0M |
| EBITDA | $-712.8M | $-712.8M | $-685.7M | $-862.7M | $950.9M |
| EPS | -2.18 | -2.18 | -2.44 | -2.77 | 0.76 |
| Gross Margin | 30.9% | 30.9% | 53.5% | 37.5% | 79.2% |
| Operating Margin | -618.9% | -618.9% | -920.4% | -1263.6% | -22.7% |
| Net Margin | -809.1% | -809.1% | -988.0% | -1512.8% | 33.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.04 | 0.04 | 0.03 | 0.03 | 0.02 |
| Current Ratio | 37.89 | 37.89 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-486.7M | $-486.7M | $-398.9M | $-513.1M | $-970.2M |
| Returns | |||||
| ROE | -10.1% | -10.1% | -9.5% | -9.3% | 2.5% |
| Valuation | |||||
| P/E | — | — | — | — | 264.22 |
| EV/EBITDA | — | — | — | — | 94.20 |
| P/B | 2.38 | 2.38 | 3.26 | 5.92 | 6.50 |
| Growth & Yield | |||||
| Revenue Growth | 9.5% | 9.5% | 35.9% | -91.9% | — |
| EPS Growth | 10.7% | 10.7% | 11.9% | -463.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-16.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.44 → -2.18
Residual
-16.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.